Publicaciones en colaboración con investigadores/as de Hospital Regional Universitario de Málaga (18)

2023

  1. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 3

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. DALBACEN cohort: Dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci

    Annals of Clinical Microbiology and Antimicrobials, Vol. 18, Núm. 1

  2. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients

    Medicine (United States), Vol. 98, Núm. 32

2018

  1. Antibiotic selection in the treatment of acute invasive infections by pseudomonas aeruginosa: Guidelines by the Spanish society of chemotherapy

    Revista Espanola de Quimioterapia, Vol. 31, Núm. 1, pp. 78-100

  2. High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial

    PLoS ONE, Vol. 13, Núm. 4

2016

  1. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens

    PLoS ONE, Vol. 11, Núm. 2

2015

  1. Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study

    HIV Medicine, Vol. 16, Núm. 10, pp. 628-634

2011

  1. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100mg once daily in HIV/Hepatitis C Virus-Coinfected Patients

    AIDS Patient Care and STDs, Vol. 25, Núm. 7, pp. 395-402

2009

  1. Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: Effect of hepatitis virus co-infection and pre-existing fibrosis

    Journal of Antimicrobial Chemotherapy, Vol. 63, Núm. 1, pp. 178-183

2007

  1. Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 5, pp. 305-310

2006

  1. Impacto de los factores demográficos y psicosociales en la no adherencia a los fármacos antirretrovirales

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 24, Núm. 6, pp. 373-378

2005

  1. Clinical status, adherence to HAART and quality of life in HIV-infected patients receiving antiretroviral treatment

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 23, Núm. 10, pp. 581-585

  2. Health-related quality of life of patients with HIV: Impact of sociodemographic, clinical and psychosocial factors

    Quality of Life Research, Vol. 14, Núm. 5, pp. 1301-1310

  3. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: The VESD study

    HIV Clinical Trials, Vol. 6, Núm. 6, pp. 320-328

2000

  1. Prevalence of primary mutations in human immunodeficiency virus with resistance to nucleoside analogues in naive human immunodeficiency virus-infected patients from Andalucía (Spain)

    Medicina Clinica, Vol. 115, Núm. 11, pp. 423-425

1998

  1. Comparative study of bacteremias caused by Enterococcus spp. with and without High-level resistance to gentamicin

    Journal of Clinical Microbiology, Vol. 36, Núm. 2, pp. 520-525

1996

  1. Prospective evaluation of fever of unknown origin in patients infected with the human immunodeficiency virus

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 15, Núm. 9, pp. 705-711